OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Liver Disease is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Critical Care Management of Acute-on-Chronic Liver Failure: Certainties and Unknowns	74
Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma	66
Liver Immunology, Immunotherapy, and Liver Cancers: Time for a Rethink?	64
Hepatic Extracellular Matrix and Its Role in the Regulation of Liver Phenotype	46
A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD	43
Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease	37
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease	32
HBV Biomarkers and Their Role in Guiding Treatment Decisions	30
Genetic and Epigenetic Basis of Drug-Induced Liver Injury	29
Genetic Contributions to Biliary Atresia: A Developmental Cholangiopathy	27
Hepatic Alveolar Echinococcosis	26
Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis	23
Physiomimetic In Vitro Human Models for Viral Infection in the Liver	22
Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems	21
Wilson Disease: Novel Diagnostic and Therapeutic Approaches	21
Mice Engrafted with Human Liver Cells	20
Role of YAP1 Signaling in Biliary Development, Repair, and Disease	20
Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies	20
Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective	19
Alcohol Plus Additional Risk Factors: Rodent Model of Liver Injury	19
Diagnosis and Management of Early Stages of ALD	18
Current and Evolving Indications for Simultaneous Liver Kidney Transplantation	16
Interleukin-17 in Liver Disease Pathogenesis	14
A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination	13
Circadian Regulation of Gene Expression and Metabolism in the Liver	13

Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity	13
Role of Complement in Liver Diseases	12
	12
Erratum to: Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics	11
Liver Neurobiology: Regulation of Liver Functions by the Nervous System	11
Primary Cilia in Hepatic Biliary Hyperplasia: Implications for Liver Diseases	11
To TIPS or Not to TIPS in High Risk of Variceal Rebleeding and Acute-on-Chronic Liver Failure	11
Role of Intestinal Barrier Disruption to Acute-on-Chronic Liver Failure	11
This Is What Metabolic Dysfunction–Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol	10
Novel Biomarkers of AKI in Cirrhosis	10
Artificial Intelligence in Hepatology: A Narrative Review	10
Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future	10
	10
Mesenchymal Stem Cell Transplantation in Liver Diseases	10
Management of Portal vein Thrombosis in Cirrhosis	10
	10
Endoscopic Advances in Hepatology	9
Hepatitis B Core-Related Antigen: From Virology to Clinical Application	8
Erratum to: Genetic Contributions to Biliary Atresia: A Developmental Cholangiopathy	8
Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease	8
Hepatitis Delta Infection: A Clinical Review	8
Erratum to: Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis	8
Toward a Liver Cell Atlas: Understanding Liver Biology in Health and Disease at Single-Cell Resolution	8
Hepatocellular Carcinoma Chemoprevention with Generic Agents	8
The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease	8
LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology	7
Screening for At-Risk Nonalcoholic Fatty Liver Disease in the Primary Care Setting	7
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms	7
Research Progress on the Role and Mechanism of IL-37 in Liver Diseases	7
Pediatric and Adult Liver Disease in Alpha-1 Antitrypsin Deficiency	7
Extracellular Vesicles and Micro-RNAs in Liver Disease	6
Scavenger Receptors: Novel Roles in the Pathogenesis of Liver Inflammation and Cancer	6
Advancements in MELD Score and Its Impact on Hepatology	6
Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?	6
The Mechanism of Interleukin-35 in Chronic Hepatitis B	6
Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD	6
Erratum to: Scavenger Receptors: Novel Roles in the Pathogenesis of Liver Inflammation and Cancer	5
Nonalcoholic Fatty Liver Disease: Current Global Burden	5
The Ways to Die: Cell Death in Liver Pathophysiology	5
Shared Mechanisms between Cardiovascular Disease and NAFLD	5
Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	5
Alcohol-Metabolizing Enzymes, Liver Diseases and Cancer	5
Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?	5
Hepatic Innervations and Nonalcoholic Fatty Liver Disease	5
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs	5
	4
Blinding in Clinical Trials for Chronic Liver Diseases	4
Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research	4
Gestational and Developmental Contributors of Pediatric MASLD	4
Bioengineered Liver Models for Investigating Disease Pathogenesis and Regenerative Medicine	4

Drug-Induced Vanishing Bile Duct Syndrome: From Pathogenesis to Diagnosis and Therapeutics	4
	4
Influence of Sex in the Development of Liver Diseases	4
Immune Checkpoint Inhibitor-Induced Liver Injury	4
	4
Mastering Core Recommendations during HEPAtology ROUNDS in Patients with Advanced Chronic Liver Disease	3
Treating Alcohol Use Disorder in Patients with Alcohol-Associated Liver Disease: Controversies in Pharmacological Therapy	3
Novel Endoscopic Bariatric Therapies for the Management of Nonalcoholic Steatohepatitis	3
Dietary Treatment for NAFLD: New Clinical and Epidemiological Evidence and Updated Recommendations	3
Pathogenesis and Management of Intestinal Failure-Associated Liver Disease	3
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis	3
Angiocrine Signaling in Sinusoidal Health and Disease	3
	3
Role of Hepatocyte Nuclear Factor 4 Alpha in Liver Cancer	3
The Ploidy State as a Determinant of Hepatocyte Proliferation	3
	3
Role of Neutrophils in the Development of Steatotic Liver Disease	3
	2
The Molecular Pathogenesis of Sarcopenia/Frailty in Cirrhosis	2
UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis	2
Early Diagnosis and Prevention of Infections in Cirrhosis	2
Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease	2
Preface (Introduction)	2
Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury	2
Beyond Varices: Complications of Cirrhotic Portal Hypertension in Pediatrics	2
Potential of HBx Gene for Hepatocarcinogenesis in Noncirrhotic Liver	2
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets	2
NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?	2
The Neglected Role of Bile Duct Epithelial Cells in NASH	2